Heparin Is Much More Than Just an Anticoagulant

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 1, 2004, Pages 93-100

  Day, Jonathan R S ^a   Landis, R C ^a   Taylor, K M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Aldosterone; Endothelium; Heparin; Inflammation; Osteoporosis; Platelets; Thyroid function test

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; DELTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MINIHEP; THROMBIN; TINZAPARIN;

ANTINEOPLASTIC ACTIVITY; DRUG ACTIVITY; HUMAN; HYPERKALEMIA; INFLAMMATION; LIPID METABOLISM; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 1242319582     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2003.10.021     Document Type: Review

References (114)

1. Hirsh J, Anand SS, Halperin JL, et al: AHA Scientific Statement: Guide to anticoagulant therapy: Heparin: A Statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol 21:e9-e33, 2001
2. Lever R, Page CP: Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140-148, 2002
3. Turnbull J, Powell A, Guimond S: Heparan sulfate: Decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11:75-82, 2001
4. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S-94S, 2001 (suppl)
5. Andersson LO, Barrowcliffe TW, Holmer E, et al: Molecular weight dependency of the heparin-potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 15:531-541, 1979
6. Roberts HR, Monroe DM, Oliver JA, et al: Newer concepts of blood coagulation. Haemophilia 4:331-334, 1998
7. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30:10363-10370, 1991
8. de Vonne TL, Mouray H: Human alpha2-macroglobulin and its antitrypsin and antithrombin activities in serum and plasma. Clin Chim Acta 90:83-85, 1978
9. Suzuki K, Kusumoto H, Deyashiki Y, et al: Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 6:1891-1897, 1987
10. Heeb MI, Griffin JH: Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem 263:11613-11616, 1988
11. Tollefsen DM, Majerus DW, Blank MK: Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 257:2162-2169, 1982
12. Rosenberg RD, Damus PS: The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248:6490-6505, 1973
13. Jordan RE: Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism. Arch Biochem Biophys 227:587-595, 1983
14. Olson ST, Bjork I, Sheffer R, et al: Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267:12528-12538, 1992
15. Lindahl U, Backstrom G, Thunberg L, et al: Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A 77:6551-6555, 1980
16. Casu B, Oreste P, Torri G, et al: The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 197:599-609, 1981
17. Valeri CR, Feingold H, Cassidy G, et al: Hypothermia-induced reversible platelet dysfunction. Ann Surg 205:175-181, 1987
18. Roth GJ, Calverley DC: Aspirin, platelets, and thrombosis: Theory and practice. Blood 83:885-898, 1994
19. Upchurch GR, Valeri CR, Khuri SF, et al: Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol 271: H528-H534, 1996
20. Fareed J, Walenga JM, Hoppensteadt DA, et al: Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost 11:199-207, 1985
21. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97:251-256, 1998
22. Rohrer MJ, Kestin AS, Ellis PA, et al: High-dose heparin suppresses platelet alpha granule secretion. J Vasc Surg 15:1000-1008, 1992
23. Eika C: Inhibition of thrombin-induced aggregation of human platelets by heparin and antithrombin 3. Scand J Haematol 8:250-256, 1971
24. Clemetson KJ, Clemetson JM: Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost 21:130-136, 1995
25. Hess D, Schaller J, Rickli EE, et al: Identification of the disulphide bonds in human platelet glycocalicin. Eur J Biochem 199:389-393, 1991
26. Beer JH, Buchi L, Steiner B: Glycocalicin: A new assay-The normal plasma levels and its potential usefulness in selected diseases. Blood 83:691-702, 1994
27. De Candia E, De Cristofaro R, Landolfi R: Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin. Circulation 99:3308-3314, 1999
28. Greinacher A, Eichler P, Lubenow N, et al: Drug-induced and drug dependent immune thrombocytopenias. Rev Clin Exp Hematol 5:166-200, 2001
29. Cimo PL, Moake JL, Weinger RS, et al: Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol 6:125-133, 1979
30. Chong BH: Heparin-induced thrombocytopenia. Aust N Z J Med 22:145-152, 1992
31. Wahl TO, Lipschitz DA, Stechschulte DJ: Thrombocytopenia associated with antiheparin antibody. JAMA 240:2560-2562, 1978
32. Kapsch DN, Adelstein EH, Rhodes GR, et al: Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Surgery 86:148-155, 1979
33. Amiral J, Wolf M, Fischer A, et al: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92:954-959, 1996
34. Amiral J, Bridey F, Dreyfus M, et al: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95-96, 1992
35. Ziporen L, Li ZQ, Park KS, et al: Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92:3250-3259, 1998
36. Denomme GA: The platelet Fc receptor in heparin-induced thrombocytopenia, in Warkentin TE, Greinacher A (eds): Heparin-Induced Thrombocytopenia (ed 2). New York, Marcel Dekker, 2001, pp 189-214
37. Chong BH, Ismail F: The mechanism of heparin-induced platelet aggregation. Eur J Haematol 43:245-251, 1989
38. Amiral J, Marfaing-Koka A, Wolf M, et al: Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88:410-416, 1996
39. Ansell J, Deykin D: Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol 8:325-332, 1980
40. Warkentin TE, Hayward CP, Boshkov LK, et al: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699, 1994
41. Visentin GP, Ford SE, Scott JP, et al: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81-88, 1994
42. Sobel M, Adelman B: Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 50:815-826, 1988
43. Greinacher A, Michels I, Liebenhoff U, et al: Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharrides. Br J Hematol 84:711-716, 1993
44. Horne MK III, Chao ES: The effect of molecular weight on heparin binding to platelet. Br J Haematol 74:306-312, 1990
45. Greinacher A, Eichler P, Lubenow N, et al: Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess in value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851, 2000
46. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 23:197-202, 1997
47. Ortel TL, Chong BH: New treatment options for heparin-induced thrombocytopenia. Semin Hematol 35:26-34, 1998 (suppl)
48. Newman PM, Swanson RL, Chong BH: Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low-molecular-weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998
49. Warkentin TE: Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 10:249-258, 1996
50. Gouault-Heilmann M, Huet Y, Contant G, et al: Cardiopulmonary bypass with a low molecular-weight heparin fraction. Lancet 2:1374, 1983
51. Frederiksen JW: Cardiopulmonary bypass in humans: Bypassing unfractionated heparin. Ann Thorac Surg 70:1434-1443, 2000
52. Mulloy B, Crane DT, Drake AF, et al: The interaction between heparin and polylysine: A circular dichroism and molecular modelling study. Braz J Med Biol Res 29:721-729, 1996
53. Page CP: One explanation of the asthma paradox: Inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 337:717-720, 1991
54. Bowler SD, Smith SM, Lavercombe PS: Heparin inhibits the immediate response in antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 147:160-163, 1993
55. Folwaczny C, Wiebecke B, Loeschke K: Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 94:1551-1555, 1999
56. Parsons CL: Epithelial coating techniques in the treatment of interstitial cystitis. Urology 49:100-104, 1997 (suppl)
57. Downing LJ, Strieter RM, Kadell AM, et al: Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 28:848-854, 1998
58. Damus PS, Hicks M, Rosenberg RD: Anticoagulant action of heparin. Nature 246:355-357, 1973
59. Klein NJ, Shennan GI, Heyderman RS, et al: Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 102:821-832, 1992
60. Hiebert LM, Jaques LB: The observation of heparin on endothelium after injection. Thromb Res 8:195-204, 1976
61. Kraemer PM: Heparin releases heparan sulfate from the cell surface. Biochem Biophys Res Commun 78:1334-1340, 1977
62. Lever R, Hoult JR, Page CP: The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 129:533-540, 2000
63. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76:301-314, 1994
64. Altieri DC, Bader R, Mannucci PM, et al: Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol 107:1893-1900, 1988
65. Altieri DC, Morrissey JH, Edgington TS: Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci U S A 85:7462-7466, 1988
66. Diamond MS, Alon R, Parkos CA, et al: Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 130:1473-1482, 1995
67. Peter K, Schwarz M, Conradt C, et al: Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation 100:1533-1539, 1999
68. Rinder CS, Bonan JL, Rinder HM, et al: Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 79:1201-1205, 1992
69. Ueda T, Rieu P, Brayer J, et al: Identification of the complement iC3b binding site in the beta 2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci U S A 91:10680-10684, 1994
70. Patel KD, Cuvelier SL, Wiehler S: Selectins: Critical mediators of leukocyte recruitment. Semin Immunol 14:73-81, 2002
71. Walcheck B, Moore KL, McEver RP, et al: Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte accumulation of P-selectin in vitro. J Clin Invest 98:1081-1087, 1996
72. Mayadas TN, Johnson RC, Rayburn H, et al: Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 74:541-554, 1993
73. Arbones ML, Ord DC, Ley K, et al: Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1:247-260, 1994
74. Labow MA, Norton CR, Rumberger JM, et al: Characterization of E-selectin-deficient mice: Demonstration of overlapping function of the endothelial selectins. Immunity 1:709-720, 1994
75. Nelson RM, Cecconi O, Roberts WG, et al: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253-3258, 1993
76. Yanak K, Spellman SR, McCarthy JB, et al: Reduction of brain injury using heparin to inhibit leukocyte accumulation in rat model of transient focal cerebral ischemia. I. Protective mechanism. J Neurosurg 85:1102-1107, 1996
77. Watt SM, Williamson J, Genevier H, et al: The heparin binding PECAM-1 adhesion molecule is expressed by CD34+ hematopoietic precursor cells with early myeloid and B lymphoid cell phenotypes. Blood 82:2649-2663, 1993
78. Ornstein DL, Zacharski LR: The use of heparin for treating human malignancies. Haemostasis 29:48-60, 1999 (suppl)
79. Karpatkin S, Pearlstein E: Role of platelets in tumor cell metastases. Ann Intern Med 95:636-641, 1981
80. McEver RP: Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J 14:585-591, 1997
81. Takada A, Ohmori K, Yoneda T, et al: Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53:354-361, 1993
82. Varki A, Varki NM: P-selectin, carcinoma metastasis and heparin: Novel mechanistic connections with therapeutic implications. Braz J Med Biol Res 34:711-717, 2001
83. Gunji Y, Gorelik E: Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48:5216-5221, 1988
84. Zhang Y, Deng Y, Luther T, et al: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320-1327, 1994
85. Engelberg H: Actions of heparin in the atherosclerotic process. Pharmacol Rev 48:327-352, 1996
86. Choi YC, Swack NS, Hsiung GD: Effect of heparin on cytomegalovirus replication. Proc Soc Exp Biol Med 157:569-571, 1978
87. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993
88. Engelberg H: Actions of heparin that may affect the malignant process. Cancer 85:257-272, 1999
89. Drake SL, Klein DJ, Mickelson DJ, et al: Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived, heparin-binding synthetic peptide. J Cell Biol 117:1331-1341, 1992
90. Cochran BH, Zullo J, Verma IM, et al: Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor. Science 226:1080-1082, 1984
91. Fager G: The PDGF A-chain contains an amino acid sequence that specifically binds to heparin causing inactivation of the growth factor. Scand J Clin Invest 199:33-36, 1990
92. Day JRS, Chaudhry AN, Hunt I, et al: Heparin-induced hyperkalemia after cardiac surgery. Ann Thorac Surg 74:1698-1700, 2002
93. Kageyama Y, Suzuki H, Saruta T: Effects of routine heparin therapy on plasma aldosterone concentration. Acta Endocrinol (Copenh) 124:267-270, 1991
94. Siebels M, Andrassy K, Vecsei P, et al: Dose-dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res 66:467-473, 1992
95. Aull L, Chao H, Coy K: Heparin-induced hyperkalemia. DICP 24:244-246, 1990
96. Durand D, Ader JL, Rey JP, et al: Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int Suppl 25:S196-S197, 1988
97. Sherman RA, Ruddy MC: Suppression of aldosterone production by low-dose heparin. Am J Nephrol 6:165-168, 1986
98. Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 98:575-586, 1995
99. Persson E: Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low-molecular-weight heparin fragment (Fragmin). Acta Med Scand Suppl 724:1-56, 1988
100. Olivecrona G, Olivecrona T: Triglyceride lipases and atherosclerosis. Curr Opin Lipidol 6:291-305, 1995
101. Teraoka J, Matsui N, Nakagawa S, et al: The role of heparin in the changes of lipid patterns during a single hemodialysis. Clin Nephrol 17:96-99, 1982
102. Fan J, Unoki H, Kojima N, et al: Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 276:40071-40079, 2001
103. Schrader J, Andersson LO, Armstrong VW, et al: Lipolytic effects of heparin and low-molecular-weight heparin and their importance in hemodialysis. Semin Thromb Hemost 16:41-45, 1990 (suppl)
104. Jaume JC, Mendel CM, Frost PH, et al: Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. Thyroid 6:79-83, 1996
105. Laji K, Rhidha B, John R, et al: Abnormal serum free thyroid hormone levels due to heparin administration. Q J Med 94:471-473, 2001
106. Mendel CM, Frost PH, Cavalieri RR: Effect of free fatty acids on the concentration of free thyroxine in human serum: The note of albumin. J Clin Endocrinol Metab 63:1394-1399, 1986
107. Mendel CM, Frost PH, Kunitake ST, et al: Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 65:1259-1264, 1987
108. Muir JM, Andrew M, Hirsh J, et al: Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. 88:1314-1320, 1996
109. Jaques BL: Heparin: An old drug with a new paradigm. Science 206:528-533, 1979
110. Avioli LV: Heparin-induced osteopenia: An appraisal. Adv Exp Med Biol 52:375-387, 1975
111. Shaughnessy SG, Young E, Deschamps P, et al: The effects of low-molecular-weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368-1373, 1995
112. Fryer A, Huang YC, Rao G, et al: Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 282:208-219, 1997
113. Petitou M, Driguez PA, Duchaussoy P, et al: Synthetic oligosaccharides having various functional domains: Potent and potentially safe heparin mimetics. Bioorg Med Chem Lett 9:1161-1166, 1999
114. Gonze MD, Salartash K, Sternbergh WC III, et al: Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 101:2658-2661, 2000